Literature DB >> 22115899

Methamphetamine-induced changes in the object recognition memory circuit.

Carmela M Reichel1, Lauren A Ramsey, Marek Schwendt, Jacqueline F McGinty, Ronald E See.   

Abstract

Chronic methamphetamine (meth) can lead to persisting cognitive deficits in human addicts and animal models of meth addiction. Here, we examined the impact of either contingent or non-contingent meth on memory performance using an object-in-place (OIP) task, which measures the ability to detect an object relative to its location and surrounding objects. Further, we quantified monoamine transporter levels and markers of neurotoxicity within the OIP circuitry and striatum. Male Long-Evans rats received an acute meth binge (4 × 4 mg/kg i.p., 2 h intervals) or self-administered meth (0.02 mg/infusion, i.v.; 7 days for 1 h/day, followed by 14 days for 6 h/day). Rats were tested for OIP recognition memory following one week of withdrawal. Subsequently, transporters for serotonin (SERT) and norepinephrine (NET) were quantified using Western blot in tissue obtained from the hippocampus, perirhinal cortex, and prefrontal cortex. In addition, striatal dopamine transporters, tyrosine hydroxylase, and glial fibrillary acidic protein were measured to assess potential neurotoxicity. Control (saline-treated) rats spent more time interacting with the objects in the changed locations. In contrast, contingent or non-contingent meth resulted in disrupted OIP performance as seen by similar amounts of time spent with all objects, regardless of location. While only acute meth binge produced signs of neurotoxicity, both meth regimens decreased SERT in the perirhinal cortex and hippocampus. Only meth self-administration resulted in a selective decrease in NET. Meth-induced changes in SERT function in the OIP circuitry may underlie memory deficits independently of overt neurotoxic effects. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22115899      PMCID: PMC3262904          DOI: 10.1016/j.neuropharm.2011.11.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  73 in total

1.  The medial frontal cortex and temporal memory: tests using spontaneous exploratory behaviour in the rat.

Authors:  J B Mitchell; J Laiacona
Journal:  Behav Brain Res       Date:  1998-12       Impact factor: 3.332

2.  Different contributions of the hippocampus and perirhinal cortex to recognition memory.

Authors:  H Wan; J P Aggleton; M W Brown
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

3.  Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice.

Authors:  Hiroyuki Kamei; Taku Nagai; Hiroko Nakano; Yuriko Togan; Masanori Takayanagi; Kenji Takahashi; Kana Kobayashi; Shigeru Yoshida; Kenji Maeda; Kazuhiro Takuma; Toshitaka Nabeshima; Kiyofumi Yamada
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

4.  Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity.

Authors:  Annabelle M Belcher; Steven J O'Dell; John F Marshall
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

5.  The effects of neurotoxic lesions of the perirhinal cortex combined to fornix transection on object recognition memory in the rat.

Authors:  A Ennaceur; J P Aggleton
Journal:  Behav Brain Res       Date:  1997-11       Impact factor: 3.332

6.  Brain serotonin transporter density and aggression in abstinent methamphetamine abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Masami Futatsubashi; Hiroyuki Okada; Yoshio Minabe; Katsuaki Suzuki; Yasuhide Iwata; Kenji J Tsuchiya; Hideo Tsukada; Masaomi Iyo; Norio Mori
Journal:  Arch Gen Psychiatry       Date:  2006-01

7.  Escalation of methamphetamine self-administration in rats: a dose-effect function.

Authors:  Osamu Kitamura; Sunmee Wee; Sheila E Specio; George F Koob; Luigi Pulvirenti
Journal:  Psychopharmacology (Berl)       Date:  2006-03-17       Impact factor: 4.530

8.  Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat.

Authors:  Jack D Shepard; David T Chuang; Yavin Shaham; Marisela Morales
Journal:  Psychopharmacology (Berl)       Date:  2006-03-23       Impact factor: 4.530

9.  Regional quantification of dopamine transporter mRNA in rat brain using a ribonuclease protection assay.

Authors:  N M Richtand; J R Kelsoe; D S Segal; R Kuczenski
Journal:  Neurosci Lett       Date:  1995-11-17       Impact factor: 3.046

10.  Profile of executive and memory function associated with amphetamine and opiate dependence.

Authors:  Karen D Ersche; Luke Clark; Mervyn London; Trevor W Robbins; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2006-05       Impact factor: 7.853

View more
  44 in total

1.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

Review 2.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

3.  Sex differences in escalation of methamphetamine self-administration: cognitive and motivational consequences in rats.

Authors:  Carmela M Reichel; Clifford H Chan; Shannon M Ghee; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2012-05-17       Impact factor: 4.530

4.  Selective, retrieval-independent disruption of methamphetamine-associated memory by actin depolymerization.

Authors:  Erica J Young; Massimiliano Aceti; Erica M Griggs; Rita A Fuchs; Zachary Zigmond; Gavin Rumbaugh; Courtney A Miller
Journal:  Biol Psychiatry       Date:  2013-09-05       Impact factor: 13.382

5.  Methamphetamine self-administration attenuates hippocampal serotonergic deficits: role of brain-derived neurotrophic factor.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Int J Neuropsychopharmacol       Date:  2014-03-20       Impact factor: 5.176

6.  Sex differences in memory and intracellular signaling after methamphetamine binge treatment.

Authors:  Anthony Klambatsen; Stephanie K Nygard; Anna J Chang; Vanya Quinones; Shirzad Jenab
Journal:  Brain Res       Date:  2019-01-07       Impact factor: 3.252

7.  Modafinil restores methamphetamine induced object-in-place memory deficits in rats independent of glutamate N-methyl-D-aspartate receptor expression.

Authors:  Carmela M Reichel; Meghin G Gilstrap; Lauren A Ramsey; Ronald E See
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

8.  Cocaine and methamphetamine induce opposing changes in BOLD signal response in rats.

Authors:  Saeid Taheri; Zhu Xun; Ronald E See; Jane E Joseph; Carmela M Reichel
Journal:  Brain Res       Date:  2016-04-18       Impact factor: 3.252

9.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

Review 10.  Chronic methamphetamine self-administration disrupts cortical control of cognition.

Authors:  Aurelien Bernheim; Ronald E See; Carmela M Reichel
Journal:  Neurosci Biobehav Rev       Date:  2016-07-20       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.